



ISHITA DRUGS & INDUSTRIES LTD.

Corp. Off.: 401, 3rd Eye II, Opp. Parimal Garden, C. G. Road, Ahmedabad-380006.

Phone : +91 92280 16100-03 | +91 79 2646 8653/7886, 2640 3214 | Fax : +91 79 2640 4961

Regd. Office & Factory : 179/1, Vasna-Iyava, Tal.: Sanand, Dist.: Ahmedabad.

Email : ishitadrugs@gmail.com | ishitadrugs@vsnl.net | URL : www.ishitadrugs.in

Date: 13th November, 2018

To,
The Company Section
The Bombay Stock Exchange
Phiroz Jijibhoy Towers
Dalal Street, Bombay- 400 001

Security Code: 524400

Dear Sir,

Sub: Outcome of Board Meeting held on 13th November, 2018 pursuant to Regulation 30 of SEBI (LODR) Regulation, 2015.

This is to inform you that the Board of directors of the Company at its meeting held today on Tuesday, the 13th Day of November, 2018 have

1. Approved the Unaudited Financial Results of the Company along with the Limited Review Report for the quarter and half year ended on 30th September, 2018 pursuant to Regulation 33 of SEBI (LODR) Regulation, 2015.
2. Approved the appointment of Ms. Niharika Shah as Company Secretary.

Hope the enclosed papers are in accordance with requirements. Please take the same on your records and oblige. Please do the needful.

Thanking You.

For, Ishita Drugs & Industries Ltd.


Authorised Signatory



"Our basic drugs in the service of humanity worldwide"

D & B D-U-N-S Number - 65-018-0359

ISHITA DRUGS AND INDUSTRIES LIMITED
 CIN: L24231GJ1992PLC017054
 Registered Office: Survey No. 179/1, Village : Vasna-Iyava, Ta. Sanand
 Ahmedabad – 382170
 Website: www.ishitadrugs.com
 Contact: +91 7226995613/14/15

Unaudited Financial Results for the Quarter and Half year Ended September 30, 2018

Particulars	Amount in Lacs except Per Share data											
	3 Months Ended			Quarter Ended			Half Year Ended			Year Ended		
	Un-audited	Un-audited	30-Sep-18	Un-audited	Un-audited	30-Sep-17	Un-audited	Un-audited	30-Sep-18	Un-audited	Un-audited	31-Mar-18
1 INCOME												
Revenue from Operations	202.67	178.22	193.98	380.89	333.99	689.98						
Other Income	2.24	1.39	5.63	3.63	3.93	11.93						
	204.907	179.61	199.61	384.52	337.92	701.91						
2 EXPENSES												
(a) Cost of Material Consumed	138.74	112.42	119.09	251.16	194.97	476.74						
(b) Purchase of Stock-In-Trade	0.00	0.00	9.28	0.00	9.28	9.23						
(c) Changes in Inventories of Finished Goods, Work-In-Progress and Stock-In-Trade	-2.12	2.99	18.37	0.87	13.95	(12.71)						
(d) Employee Benefit Expense	22.31	20.06	19.96	42.37	39.87	79.99						
(e) Finance Cost	0.38	1.19	0.55	1.57	1.49	11.26						
(f) Depreciation, Depletion and Amortisation Expense	3.91	3.40	3.00	7.31	7	13.61						
(g) Other Expense	31.05	29.37	22.49	60.42	57.6	90.76						
1												
2												
3												
4												
5												
Total Other Expenses	31.05	29.37	22.49	60.42	57.6	90.76						
Total Expenses	194.27	169.43	192.74	363.70	324.16	668.88						
Total Profit before Exceptional Items and Tax	10.63	10.19	6.87	20.82	13.76	33.03						
4 Exceptional Items	0	0.00	0.00	0	0	0						
5	10.63	10.19	6.87	20.82	13.76	33.03						
6 Tax Expense												
7 Current Tax	2.31	2.29	1.71	4.60	3.604	8.71						
8 Deferred Tax	0.00	0.00	0.00	0	0	(0.46)						
9	2.31	2.29	1.71	4.60	3.604	8.25						
10 Net Movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0.00	0.00	0.00	0	0	0						
11 Net Profit Loss for the period from continuing operations	8.32	7.90	5.16	16.22	10.16	24.78						



NOTES

1. The above Financial Results were reviewed by the Audit Committee and thereafter were approved and taken on record by the Board of Directors in their meeting held on November 13, 2018.
2. The Limited Review of the results has been completed by the Statutory Auditors of the Company.
3. As per Indian Accounting Standard (IndAS) "Operating Segment", the Company's business falls within a single business segment viz. "Pharmaceutical Business".
4. The financial results for the quarter and half year ended 30th September, 2018 are also Ind AS compliant. The management has exercised necessary due diligence to ensure that the financial results give a true and fair view. This information has not been subjected to limited review or audit.
5. Previous quarter's amounts have been re-grouped/re-classified, wherever considered necessary to make them comparable with those of the current quarter.
6. Results are available at Company's website www.ishitadrugs.com and also at www.bseindia.com.

For, **ISHITA DRUGS AND INDUSTRIES LIMITED**



Place **Ahmedabad**
Date **13-Nov-18**

JAGDISH AGRAWAL
MANAGING DIRECTOR
DIN: 01031687

ISHITA DRUGS AND INDUSTRIES LIMITED
CIN: L24231GJ1992PLC017054
Registered Office: Survey No. 179/1, Village : Vasna-Iyava, Ta. Sanand
Ahmedabad – 382170
Website: www.ishitadrugs.com
Contact: +91 9228016100

Statement of Assets and Liabilities

Amount in ₹

Particulars	Half Year Ended	Previous Year Ended	
	6 Months Ended	12 Months Ended	
	Unaudited	Audited	
	30-Sep-18	31-Mar-18	
ASSETS			
1	Non-current assets		
	Property, plant and equipment	11401773	11879886
	Capital work-in-progress		
	Investment property		
	Goodwill		
	Other intangible assets		
	Intangible assets under development		
	Biological assets other than bearer plants		
	Investments accounted for using equity method		
	Non-current financial assets	11401773	11879886
	Non-current investments	1592254	1592254
	Trade receivables, non-current		
	Loans, non-current		498200
	Other non-current financial assets		
	Total Non-current financial assets	1592254	2090454
	Deferred tax assets (net)		
	Other non-current assets		
	Total Non-current Assets	12994027	13970340
2	Current assets		
	Inventories	4730185	7200886
	Current financial assets		
	Current investments	34937909	29936585
	Trade receivables, current	16823261	8215528
	Cash and cash equivalents	107895	251974
	Bank balance other than cash and cash equivalents	16874	6500088
	Loans, current	913522	736491
	Other current financial assets	5375138	5377578
	Total current financial assets	58174599	51018244
	Current tax assets (net)		
	Other current assets		
	Total Current Assets	62904784	58219130
3	Non-current assets classified as held for sale		
4	Regulatory deferral account debit balances and related deferred tax Assets		
	TOTAL ASSETS	75898811	72189470



/s/

EQUITIES AND LIABILITIES			
1	Equity		
	Equity attributable to owners of Parent		
	Equity share capital	29903000	29903000
	Other equity	32343097	30720893
	Total Equity attributable to owners of Parent	62246097	60623893
	Non controlling interest		
	Total Equity	62246097	60623893
2	Liabilities		
	Non-current liabilities		
	Non-current financial liabilities		
	Borrowing, non-current	1043920	849413
	Trade payables, non-current		
	Other non-current financial liabilities		
	Total Non-current financial liabilities	1043920	849413
	Provisions, non-current		
	Deferred tax liabilities (net)	593317	593317
	Deferred government grants, Non-current Other non-current liabilities		
	Total Non-current liabilities	1637238	1442730
	Current liabilities		
	Current financial liabilities		
	Borrowing, current	1049733	417537
	Trade payables, current	7648207	5616188
	Other current financial liabilities		
	Total current financial liabilities	8697940	6033725
	Other current liabilities	1793699	2932592
	Provisions, current	1523838	1156530
	Current tax liabilities (Net)		
	Deferred government grants, Current		
	Total current liabilities	12015476	10122847
3	Liabilities directly associated with assets in disposal group classified as held for sale		
4	Regulatory deferral account credit balances and related deferred tax liability		
	Total Liabilities		
	Total Equity and Liabilities	75898811	72189470

For, ISHITA DRUGS AND INDUSTRIES LIMITED



Jagdish Agrawal

JAGDISH AGRAWAL

MANAGING DIRECTOR

Place Ahmedabad

Date 13-Nov-18

DIN: 01031687



PRATIK K KIKANI & ASSOCIATES

CHARTERED ACCOUNTANTS

MRN: 180309 FRN:145950W

PROPRIETOR: PRATIK KAUSHIKKUMAR KIKANI

PAN: ATVPK1876E

To,
The Board of Directors,
Ishita Drugs & Industries Ltd.
Ahmedabad.

LIMITED REVIEW REPORT

We have reviewed the accompanying statement of unaudited financial results of **ISHITA DRUGS AND INDUSTRIES LTD** for the period ended **30th September, 2018** (The Statement) being submitted by the Company pursuant to the requirement of Regulation 33 of SEBI (Listing of Obligations and Disclosure Requirements) Regulation,2015, read with SEBI Circular No.CIR/CFD/FAC/62/2016 dated 5th July, 2016. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of interim financial information performed by the independent auditor of the entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with Indian accounting standards prescribed under section 133 of Companies Act, 2013, read with relevant rules issued there under and another recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of SEBI (Listing of Obligations and Disclosure Requirements) Regulation,2015, read with SEBI Circular No.CIR/CFD/FAC/62/2016 dated 5th July, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For and on behalf of
PRATIK KAUSHIKKUMAR KIKANI
Chartered Accountants

CA Pratik Kaushikkumar Kikani
Proprietor

MRN: 180309

FRN: 145950W

Date: 13/11/2018

Place: Ahmedabad



For, PRATIK K. KIKANI & ASSOCIATES
Chartered Accountants

Kikani Pratik
Proprietor